Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors
Vor Bio (Nasdaq: VOR) has appointed Mr. Erez Kalir to its Board of Directors, creating a new board seat following a recent private investment in public equity (PIPE) financing led by Reid Hoffman. Kalir will serve as director designee of Hoffman's investment fund, Reprogrammed Interchange,
Currently Managing Member of Martial Eagle Fund and Venture Partner at FJ Labs, Kalir brings extensive experience in biotech investments and entrepreneurship. He authors the Biotech Frontiers newsletter for Porter & Co. and previously worked at Tiger Management with Julian H. Robertson, advising on biotech and healthcare investments.
Kalir's appointment strengthens Vor Bio's leadership as the company advances its trem-cel platform and VCAR33 through regulatory approval. His background includes an MSc in cell biology from Oxford as a Rhodes Scholar, a JD from Yale Law School, and an A.B. from Stanford University.
Vor Bio (Nasdaq: VOR) ha nominato il Sig. Erez Kalir nel suo Consiglio di Amministrazione, creando un nuovo seggio a seguito di un recente finanziamento di investimento privato in capitale pubblico (PIPE) guidato da Reid Hoffman. Kalir servirà come direttore designato del fondo di investimento di Hoffman, Reprogrammed Interchange.
Attualmente Managing Member del Martial Eagle Fund e Venture Partner presso FJ Labs, Kalir porta con sé una vasta esperienza negli investimenti biotech e nell'imprenditorialità. È autore della newsletter Biotech Frontiers per Porter & Co. e ha lavorato in precedenza presso Tiger Management con Julian H. Robertson, offrendo consulenze sugli investimenti biotech e sanitari.
La nomina di Kalir rafforza la leadership di Vor Bio mentre l'azienda avanza nella sua piattaforma trem-cel e VCAR33 attraverso l'approvazione regolatoria. Il suo percorso include un MSc in biologia cellulare da Oxford come Rhodes Scholar, un JD dalla Yale Law School e un A.B. dalla Stanford University.
Vor Bio (Nasdaq: VOR) ha nombrado al Sr. Erez Kalir en su Junta Directiva, creando un nuevo asiento en la junta tras una reciente inversión privada en capital público (PIPE) liderada por Reid Hoffman. Kalir servirá como director designado del fondo de inversión de Hoffman, Reprogrammed Interchange.
Actualmente Managing Member del Martial Eagle Fund y Venture Partner en FJ Labs, Kalir aporta una amplia experiencia en inversiones en biotecnología y emprendimiento. Es autor del boletín Biotech Frontiers para Porter & Co. y anteriormente trabajó en Tiger Management con Julian H. Robertson, asesorando sobre inversiones en biotecnología y salud.
La nombramiento de Kalir fortalece el liderazgo de Vor Bio mientras la compañía avanza en su plataforma trem-cel y VCAR33 hacia la aprobación regulatoria. Su trayectoria incluye un MSc en biología celular de Oxford como Rhodes Scholar, un JD de la Yale Law School y un A.B. de la Stanford University.
Vor Bio (Nasdaq: VOR)는 Erez Kalir를 이사회에 임명하여, Reid Hoffman이 이끄는 최근의 사모 공공 자본 투자(PIPE) 자금을 통해 새로운 이사석을 추가했습니다. Kalir는 Hoffman's 투자 기금인 Reprogrammed Interchange의 지정된 이사로 활동할 예정입니다.
현재 Martial Eagle Fund의 매니징 멤버이자 FJ Labs의 벤처 파트너인 Kalir는 생명공학 투자와 기업가정신에 대한 폭넓은 경험을 가지고 있습니다. 그는 Porter & Co.를 위한 Biotech Frontiers 뉴스레터의 저자이며, Julian H. Robertson과 함께 Tiger Management에서 일하며 생명공학 및 의료 투자에 대해 자문했습니다.
Kalir의 임명은 Vor Bio의 리더십을 강화하며, 회사가 trem-cel 플랫폼과 VCAR33의 규제 승인을 진행하는 데 도움을 줍니다. 그의 배경에는 로즈 장학생으로서 옥스포드 대학에서 석사학위를, 예일 로스쿨에서 법학 박사(JD)를, 스탠포드 대학교에서 A.B.를 취득한 이력이 포함됩니다.
Vor Bio (Nasdaq: VOR) a nommé M. Erez Kalir au sein de son Conseil d'Administration, créant ainsi un nouveau siège suite à un récent investissement privé en capital public (PIPE) dirigé par Reid Hoffman. Kalir agira en tant que directeur désigné du fonds d'investissement de Hoffman, Reprogrammed Interchange.
Actuellement Managing Member du Martial Eagle Fund et Venture Partner chez FJ Labs, Kalir possède une vaste expérience dans les investissements en biotechnologie et l'entrepreneuriat. Il est l'auteur de la newsletter Biotech Frontiers pour Porter & Co. et a précédemment travaillé chez Tiger Management avec Julian H. Robertson, conseillant sur les investissements en biotechnologie et en santé.
La nomination de Kalir renforce le leadership de Vor Bio alors que l'entreprise fait progresser sa plateforme trem-cel et VCAR33 vers l'approbation réglementaire. Son parcours comprend un MSc en biologie cellulaire d'Oxford en tant que boursier Rhodes, un JD de la Yale Law School et un A.B. de l'Université de Stanford.
Vor Bio (Nasdaq: VOR) hat Herrn Erez Kalir in seinen Vorstand berufen und damit einen neuen Vorstandssitz geschaffen, nachdem kürzlich eine private Investition in öffentliche Aktien (PIPE) unter der Leitung von Reid Hoffman getätigt wurde. Kalir wird als designierter Direktor des Investmentfonds von Hoffman, Reprogrammed Interchange, fungieren.
Derzeit ist er Managing Member des Martial Eagle Fund und Venture Partner bei FJ Labs. Kalir bringt umfangreiche Erfahrung in Biotech-Investitionen und Unternehmensgründungen mit. Er ist Autor des Biotech Frontiers Newsletters für Porter & Co. und hat zuvor bei Tiger Management unter Julian H. Robertson gearbeitet, wo er zu Biotech- und Gesundheitsinvestitionen beraten hat.
Kaliers Ernennung stärkt die Führung von Vor Bio, während das Unternehmen seine trem-cel-Plattform und VCAR33 auf dem Weg zur regulatorischen Genehmigung vorantreibt. Sein Hintergrund umfasst einen MSc in Zellbiologie von Oxford als Rhodes Scholar, einen JD von der Yale Law School und einen A.B. von der Stanford University.
- Secured new PIPE financing led by prominent investor Reid Hoffman
- Added strategic board member with extensive biotech investment experience
- Strengthened governance structure through board expansion
- None.
CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of Directors. The appointment represents a new seat on Vor Bio’s Board of Directors, which has been created in connection with the recent private investment in public equity financing (PIPE) which was led by Reid Hoffman. Mr. Kalir will serve as the director designee of Reprogrammed Interchange, LLC, Mr. Hoffman’s investment fund.
Mr. Kalir brings a wealth of experience as an investor, entrepreneur, and thought leader with a deep focus on life sciences and technology. Currently the Managing Member of Martial Eagle Fund and a Venture Partner at FJ Labs—renowned for its leadership in early-stage venture investments—Mr. Kalir is widely recognized for his strategic acumen and ability to drive growth in innovative industries. In addition to his investment leadership, Mr. Kalir authors the influential Biotech Frontiers newsletter for Porter & Co., offering incisive analysis on cutting-edge biotech companies. His interdisciplinary expertise in biology, finance, and law uniquely positions him to contribute to Vor Bio’s mission of advancing breakthrough innovations in cancer and beyond.
"We are excited to welcome Mr. Kalir to our Board of Directors," said Dr. Robert Ang, President and CEO of Vor Bio. "Mr. Kalir’s extensive experience in the biotech sector, combined with his track record of fostering innovation, will be invaluable as we continue to execute on our vision to revolutionize blood cancer treatment." Matthew R. Patterson, Chairman of Vor Bio, added, “I welcome Mr. Kalir to the Board of Directors, and we look forward to working with him as Vor continues to advance its clinical programs and execute its strategic vision.”
Prior to his current roles, Mr. Kalir worked with legendary investor Julian H. Robertson at Tiger Management, advising on investments in biotech and health care. He co-founded and led Sabretooth Capital, a hedge fund managing assets for prominent institutions and families, and further honed his expertise at Eton Park and McKinsey & Co.
"I have followed Vor Bio from the time the company's scientific founder Dr. Siddhartha Mukherjee published his groundbreaking paper in PNAS on gene-edited stem cells enabling CD33 immune therapy, through Vor Bio's early venture financings, IPO, and progress as a public company. Among the many companies pursuing breakthrough innovations in biotech, I would be hard pressed to identify one whose potential to change the course of a lethal cancer is more promising than Vor's,” said Mr. Kalir. “I look forward to working with Vor Bio's world-class management team and Board to advance their trem-cel platform and VCAR33 through the regulatory approval process, with the goal of enabling life-changing impacts for patients."
Mr. Kalir is a Rhodes Scholar and holds an MSc in cell biology from Magdalen College, Oxford, a JD from Yale Law School, and an A.B. with highest honors from Stanford University.
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “can,” “continue,” “could,” “design,” “enable,” “expect,” “initiate,” “intend,” “may,” “on-track,” “ongoing,” “plan,” “potential,” “should,” “target,” “update,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio’s statements regarding the potential of engineered hematopoietic stem cells to enable targeted therapies in the post-transplant setting, potential regulatory approval of its product candidates, the potential of its product candidates to change the course of disease in patients it seeks to treat and enable life-changing impacts, and other statements that are not historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Vor Bio’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products; the success of Vor Bio’s in-house manufacturing capabilities and efforts; and availability of funding sufficient for its foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in Vor Bio’s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.
Contact:
Investors & Media
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com
FAQ
What is the significance of Erez Kalir joining Vor Bio's (VOR) board of directors?
How is Erez Kalir's appointment to VOR connected to Reid Hoffman's investment?
What is Vor Bio's (VOR) current development focus in 2025?
What relevant experience does Erez Kalir bring to Vor Bio's board?
